Medical Professionals Gather in Bethesda to Expand US-Korea Healthcare Exchanges
Medical professionals and industry officials gathered in Bethesda on October 3 to expand health care exchanges between South Korea and the United States, focusing on foreign patient attraction and cellular and gene therapies, koreatimes.com reported.
Key Clinical Takeaways:
- The 2026 Medical Korea event took place at the Bethesda North Marriott Hotel in Maryland, drawing approximately 40 medical experts and industry officials.
- Discussions covered South Korea’s national health insurance structure, precision medicine training programs, and strategies for moving Korean biotech firms into the United States market.
- Representatives from the Embassy of Korea, the Korea Health Industry Development Institute, and local legal and health organizations participated in the program.
Bethesda Medical Korea Event Draws Industry Officials
The 2026 Medical Korea event convened under the sponsorship of the Embassy of Korea and the Korea Health Industry Development Institute. KAMTOUR, represented by head Jiyeon Hwang, organized the gathering of roughly 40 participants.
During his opening remarks, Kim Choong-hwan, health and welfare attaché at the Embassy of Korea, noted that bilateral ties have expanded across multiple sectors. “Strong Korea-U.S. alliance relations have developed widely in various fields for a long period, and recently, mutual exchanges are active in clinical and pharmaceutical bio sectors as well,” Kim stated. He added an expectation that the event would deepen cooperation in the healthcare field.
Presentations Highlight Insurance Systems and Cellular Therapies
The program featured several technical presentations addressing regulatory frameworks and clinical practices in both nations. Koh Han-kyung, managing attorney at Brighton Law Office based in Seocho-gu, Seoul, outlined South Korea’s health insurance framework and the specific regulations governing the attraction of international patients.
Paul Kim, chief executive officer of Matica Biotechnology—the cell and gene therapy contract development and manufacturing organization operated in the U.S. by CHA Biotech—addressed the practical aspects of Korean biotech expansion into the American market, detailing specific case studies and operational takeaways.
Roundtable Focuses on Cross-Border Exchange and Institutional Practices
Following the presentations, a roundtable session brought together the guest speakers alongside Jeon Ha-reum, a health specialist from the World Bank. The panel addressed questions concerning South Korea’s national health insurance mechanisms and the protocols involved in treating overseas patients, fostering discussion on mutual understanding of institutional practices between the two countries.
Bilateral health initiatives between South Korea and the United States continue to build on formal diplomatic ties and established clinical research partnerships.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.